Dr David Roblin, the former Site Head and Head of Research for Pfizer's European Research & Development HQ, has been appointed as the new Chief Operating Officer and Director of Translation of the Francis Crick Institute.<?UMBRACO_MACRO linkfullsize="0" image="5139" imgsize="150" imgcredit="0" floatright="0" imgcaption="0" macroAlias="Imagewithcaption" />
David will assume the role of COO on 1st September 2014 from the Crick's current COO, John Cooper. David will also lead translational activities for the Crick as it accelerates its science for health and wealth benefits.
David has held significant leadership roles in his pharmaceutical career, with general management, research, development and commercial responsibilities. He is regarded as a leader in translational research and during his tenure at Pfizer and Bayer he was instrumental in the successful development of several important medicines including azithromycin, ciprofloxacin, moxifloxacin, mariviroc, genotropin and sildenafil. Since he left Pfizer in early 2011, David has been Chief Medical Officer and a Non-Executive Director to a number of Biotechs. He also serves on the Major Awards Committee of the UK's Biomedical Catalyst Fund.
David has a first class honours degree in Biochemistry from University College London and later qualified with Honours in Medicine from St George's Hospital in London. He practised medicine at a variety of London teaching hospitals before joining the pharmaceutical industry in 1995.
Sir Paul Nurse, Director of the Francis Crick Institute, said: "I am delighted to welcome David to the Crick. His expertise and research knowledge will be crucial as we work towards the opening of the institute in 2015."
Dr David Roblin said: "I am excited to be joining the Crick at such an important moment in its development. To be involved in creating Europe's largest research institute on a single site and a world-leading centre of biomedical research and innovation is a huge opportunity."
To read the full press release click here.